pf-05221304
Showing 1 - 5 of 5
NASH (Nonalcoholic Steatohepatitis), NAFLD (Nonalcoholic Fatty Liver Disease) Trial (PF-05221304, Placebo)
Withdrawn
- NASH (Nonalcoholic Steatohepatitis)
- NAFLD (Nonalcoholic Fatty Liver Disease)
- PF-05221304
- Placebo
- (no location specified)
Aug 19, 2021
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis Trial in Worldwide (Placebo, PF-05221304)
Completed
- Nonalcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
- Placebo
- PF-05221304
-
Bakersfield, California
- +139 more
Dec 7, 2020
Healthy Trial in Hachioji-shi (PF-05221304, Placebo)
Completed
- Healthy
- PF-05221304
- Placebo
-
Hachioji-shi, Tokyo, JapanP-one Clinic, Keikokai Medical Corporation
Nov 26, 2018
Normal Healthy Trial in New Haven (PF-05221304, Placebo)
Completed
- Normal Healthy
- PF-05221304
- Placebo
-
New Haven, ConnecticutNew Haven Clinical Research Unit
May 22, 2018